Technology & Products
AND WHAT WE MAKE OF IT: OUR PRODUCTS
Marinomed develops therapies specifically for anti-viral and immunological diseases.
Marinomed has devoted its discovery and research efforts to the evolution of MAVIREX, a technology platform for the development of therapies that target more than 200 different respiratory virus strains based on polymers derived from red seaweed. The huge potential of this technology is reflected by Carragelose®, a unique broadly active anti-viral compound for treating respiratory diseases.
Safety and antiviral effectiveness have been established in clinical trials involving both adults and children. The compound is approved for marketing in the EU as part of an anti-viral OTC product portfolio targeting the common cold and influenza. Further novel anti-viral products derived from MAVIREX are currently being developed.
These products comprise combinations e.g. in the indication influenza, products for at-risk patients for the prevention and treatment of respiratory virus infections that may cause a worsening of an underlying disease such as asthma, allergic rhinitis and COPD as well as novel treatments of autoimmune diseases.
MAM-06.301 is an anti-allergy compound and provides an effective and safe alternative to corticosteroids and anti-histamines.